Results 61 to 70 of about 3,103 (173)

Southern African HIV Clinicians Society guideline on pre-exposure prophylaxis to prevent HIV

Southern African Journal of HIV Medicine
No Abstract available.
Pippa Macdonald, Gonasagrie Nair, Camilla Wattrus, Saiqa Mullick, Melanie Pleaner, Elzette Rousseau, Hasina Subedar, Dvora Joseph-Davey, Johan Hugo, Sinead Delany-Moretlwe, Linda-Gail Bekker   +10 more
doaj   +1 more source

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Emerging Infectious Diseases
A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine ...
Eisuke Adachi, Ayako Sedohara, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, Hiroshi Yotsuyanagi   +8 more
doaj   +1 more source

Cabotegravir Sodium

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025

Eurosurveillance
Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation.
Valentina Mazzotta
doaj   +1 more source

Cabotegravir and Rilpivirine

American Journal of Health-System Pharmacy, 2021
openaire   +2 more sources

Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084

Journal of the International AIDS Society
Introduction HPTN 084 found that long‐acting cabotegravir (CAB‐LA) was well‐tolerated and significantly reduced the risk of HIV acquisition in women compared to tenofovir disoproxil fumarate/emtricitabine (F/TDF).
Mark A. Marzinke, Brett Hanscom, Daniel Haines, Kimberly K. Scarsi, Yaw Agyei, Estelle Piwowar‐Manning, Craig W. Hendrix, Ryann Gollings, Scott Rose, Carrie Mathew, Ravindre Panchia, Elizabeth Spooner, Nishanta Singh, Peter Bock, Alex R. Rinehart, Susan L. Ford, James F. Rooney, Lydia Soto‐Torres, Myron S. Cohen, Mina C. Hosseinipour, Sinead Delany‐Moretlwe, HPTN 084 Study Team   +21 more
doaj   +1 more source

Oral pre-exposure prophylaxis implementation in South Africa: a case study of USAID-supported programs

Frontiers in Reproductive Health
Since the introduction of oral pre-exposure prophylaxis (PrEP) in 2016, countries have successfully scaled-up PrEP to populations at risk of HIV acquisition, including key populations, serodiscordant couples and pregnant women.
Jerome Wendoh Milimu, Lauren Parmley, Mahlodi Matjeng, Mathata Madibane, Mandisi Mabika, Jacques Livingston, Joseph Lawrence, Orapeleng Motlhaoleng, Hasina Subedar, Rethabile Tsekoa, Zandile Mthembu   +10 more
doaj   +1 more source

Cabotegravir

Australian Prescriber, 2022
openaire   +2 more sources

Long-Acting Cabotegravir for HIV Prevention [PDF]

JAMA, 2022
Joshua M, Sharfstein, Amy, Killelea, Derek, Dangerfield   +2 more
openaire   +2 more sources

What does the scale‐up of long‐acting HIV pre‐exposure prophylaxis mean for the global hepatitis B epidemic?

Journal of the International AIDS Society
Introduction The HIV and hepatitis B virus (HBV) epidemics are interconnected with shared routes of transmission and specific antiviral drugs that are effective against both viruses. Nearly, 300 million people around the world live with chronic HBV, many
Amir M. Mohareb, Menan Gérard Kouamé, Marcellin Nouaman, Arthur Y. Kim, Joseph Larmarange, Anne M. Neilan, Karine Lacombe, Kenneth A. Freedberg, Anders Boyd, Patrick Coffie, Emily P. Hyle   +10 more
doaj   +1 more source